test of islet cell antibodies was recently improved by the development of a two-colour immunofluorescence assay using a monoclonal proinsulin antibody to detect islet B cells. The aim of this study was to test whether in this new assay the prevalence and titre of ICA were affected by the time of incubation carried out in the presence of aprotinin (Trasylol) as an inhibitor of proteolysis. The end-point titre of ICA was therefore determined in sera from 70 children aged 0.6 to 15 years with recent onset Type 1 (insulin-dependent) diabetes mellitus, 50 healthy control subjects and 97 non-diabetic siblings of Type 1 diabetic children. In the conventional twocolour assay, ICA was positive in 53/70 (76%) Type 1 diabetic patients, 1/50 control subjects and 2/97 siblings after 30 min incubation. Prolonged incubation for 18 h increased the prevalence of ICA positive samples to 62/70 (89%) in the diabetic patients and to 2/50 in the control subjects, while the prevalence among the siblings was unchanged. Of the ICA positive non-diabetic subjects, one control child has a father with Type I diabetes, and one of the siblings subsequently developed Type 1 diabetes. In the diabetic patients the median titre was 1 : 32 for the 30 min incubation, and it increased to 1:64 for the 18h incubation (p<0.001). A marked prozone effect was seen; 16% of the samples from the Type 1 diabetic children sera were negative at a 1 : 2 dilution, but were found positive at higher dilutions. In conclusion, an 18 h incubation increases the end point titres and the prevalence of ICA in the two-colour ICA assay in Type 1 diabetic children of recent onset. The prevalence and levels of ICA among these patients may be larger than hitherto expected.
Summary. The conventional indirect immunofluorescence
test of islet cell antibodies was recently improved by the development of a two-colour immunofluorescence assay using a monoclonal proinsulin antibody to detect islet B cells. The aim of this study was to test whether in this new assay the prevalence and titre of ICA were affected by the time of incubation carried out in the presence of aprotinin (Trasylol) as an inhibitor of proteolysis. The end-point titre of ICA was therefore determined in sera from 70 children aged 0.6 to 15 years with recent onset Type 1 (insulin-dependent) diabetes mellitus, 50 healthy control subjects and 97 non-diabetic siblings of Type 1 diabetic children. In the conventional twocolour assay, ICA was positive in 53/70 (76%) Type 1 diabetic patients, 1/50 control subjects and 2/97 siblings after 30 min incubation. Prolonged incubation for 18 h increased the prevalence of ICA positive samples to 62/70 (89%) in the diabetic patients and to 2/50 in the control subjects, while the prevalence among the siblings was unchanged. Of the ICA positive non-diabetic subjects, one control child has a father with Type I diabetes, and one of the siblings subsequently developed Type 1 diabetes. In the diabetic patients the median titre was 1 : 32 for the 30 min incubation, and it increased to 1:64 for the 18h incubation (p<0.001). A marked prozone effect was seen; 16% of the samples from the Type 1 diabetic children sera were negative at a 1 : 2 dilution, but were found positive at higher dilutions. In conclusion, an 18 h incubation increases the end point titres and the prevalence of ICA in the two-colour ICA assay in Type 1 diabetic children of recent onset. The prevalence and levels of ICA among these patients may be larger than hitherto expected.
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Islet cell antibodies (ICA), first described in 1974 [1, 2] by an indirect immunofluorescence one-colour assay, are thought to be a marker for Type 1 diabetes. The prevalence of ICA in Type 1 diabetic children at the time of diagnosis or within recent clinical onset varies from 51-85% [3] [4] [5] [6] [7] [8] [9] [10] [11] . Besides differences in patient selection, this variation in prevalence of ICA might be explained by differences in sensitivity between ICA assays [12, 13] . Early attempts to quantitate ICA were inconclusive [4] , and little attention has been paid to a possible relationship between levels of ICA and the progression of Type 1 diabetes. Recently, one study reported a positive correlation between complement-fixing ICA (CF-ICA) and preservation of B-cell function [10] , while another [14] found a positive correlation between the titre of ICA at diagnosis and the rate of loss of pancreatic B-cell function evaluated by fasting Cpeptide during the first 2.5 years of insulin therapy. However, ICA may occur up to 8 years before the clinical onset of Type 1 diabetes [15] . The presence of ICA during a prediabetic period suggests that these antibodies might be directly associated with pancreatic Bcell destruction or serve as a marker for previous destructive events. Accordingly, determination of ICA might be used in screening attempts to find individuals at risk to develop Type I diabetes. If the ICA titre is to be employed as a prognostic test in prediabetic and Type 1 diabetic patients, the determination of titre levels requires an accurate and reproducible method.
Recently, we reported an accurate two-colour immunofluorescence ICA assay which substantially reduces the risk for false negative ICA reactions [16] . It has been suggested that a prolonged incubation with a protease inhibitor improves the sensitivity of the conventional one-colour ICA assay [17] .
We have therefore evaluated the effect of incubation time on the ICA levels detected in the two-colour immunofluorescence assay. The aims of our study were to find the optimal time for incubation and to determine the prevalence and levels of ICA in recently diag- 
Subjects and methods

Subjects
In a first series of experiments, randomly collected serum samples from 30 recent onset Type 1 diabetic children aged 2-16 years (mean 9.9 years +4.4 SD, median 10.5 years) were analysed to establish the kinetics of ICA binding to its antigen. In a second series of experiments we analysed consecutively collected sera from 70 Type 1 diabetic patients aged 0.6-15 years (mean 9.0years+4.3 SD, median 10 years) who were diagnosed at different pediatric departments in Sweden (Table 1) . These serum samples were obtained within one month after the initiation of insulin therapy. A first control group consisted of 50 children aged 0.3-15 years (mean 7.9 years + 4.6 SD, median 8 years) selected at random. All 50 control subjects answered a questionnaire regarding chronic diseases, autoimmunity or infections. All control subjects were included despite reported disease among themselves or their first degree family members. A second control group consisted of 97 non-diaberic siblings of Type I diabetic children aged 10-27years (mean 16.1 years_+4.8 SD, median 16 years) ( Table 1 ). All serum samples were collected and stored at-20~ or-70~ for up to 30 months before analysis.
Me~o~
Cryostat sections of unfixed frozen human pancreas of cadaveric kidney donors of blood group 0 were used in the indirect two-colour immunofluorescence assay [16] . Two different pancreata were used throughout all the assays, one to test the diabetic children and the control subjects and another to test the siblings. Frozen sections were cut 1-3 ~tm thin and put on slides. The sections were allowed to dry and either incubated directly or stored at-70~ Stored sections were dried with a fan for 30 min before use. In the first incubation, 25 ~tl serum diluted in phosphate buffered saline (PBS) containing the monoclonal proinsulin (GS9A8) antibody [18] in a final dilution of 1:1000 was added as described previously [16] . The first incubation was performed in a dark moist chamber either at room temperature for 30 rain or at+4~ for 18 h or 24 h. Aprotinin (Trasylol, Bayer AG, Leverkusen, FRG), 0.47 mg/ml, was added to prevent proteolytic degradation of the pancreatic tissue [17] . Aprotinin did not affect end point titres of ICA in the 30-min incubation assay at room temperature (data not shown). After the first incubation the slides were washed in PBS three times each for 5 min. Excess PBS was wiped off and the sections incubated with 25 p~l of a mixture of the two fluorescent second antibodies. Texas red labelled sheep antimouse IgG (N 2031, species specific, Amersham, Buckinghamshire, UK) was used to visualize the monoclonal proinsulin antibody and fluorescein isothiocyanate (FITC) conjugated rabbit anti-human IgG (Code F 202, Dako, Copenhagen, Denmark) to detect bound ICA. Undiluted FITC-labelled anti-human IgG and Texas red labelled anti-mouse IgG were centrifuged separately at 100000 g (Beckman Airfuge, Palo Alto, Calif, USA) for 5-10 rnin immediately before use, and were then mixed in equal proportions to give a final 1 : 20 dilution of each antibody. Before centrifugation and mixing, 9 parts undiluted FITC-labelled anti-human IgG was absorbed to one part mouse IgG covalently bound to agarose (Jackson, Immuno Research, Avondale, Penn, USA) by shaking at+4~ in the dark for 60 rain. The agarose was then pelleted by centrifugation at 8000 g for 1 rain, the supernatant fluid removed and the pellet of agarose beads centrifuged once more to allow more of unabsorbed FITC-labelled antibodies to be recovered. The second incubation was performed in a dark moist chamber for 30 rain at room temperature. The slides were then washed three times in PBS for 5 rain each and mounted in glycerol TRIS HC1 (pH 8.4). Microscopic evaluation was done on coded slides in an Olympus fluorescence microscope with epi-illumination (Olympus BH 2) by at least two independent observers. The filters used were EY 455 (exciter) and O515 (barrier) for the FITC fluorescence and EO 530 (exciter) and O 590 (barrier) for the Texas red fluorescence. Sera were diluted 1 : 2, 1 : 4, 1 : 8, etc. until ICA was no longer detected. The end point titre was defined as the highest titre of detectable ICA. In the prolonged incubations, all samples were first screened at dilutions 1 : 2 and l : 64. The negative sera were then retested at dilution 1 : 8; this avoided the possibility that high titre positive sera which were negative at a low dilution would be recorded as negative. The positive sera were further tested to decide end-point titre. By this procedure all sera were tested in at least two different assays.
In each assay one positive standard sample in five different dilutions and one negative sample in three dilutions were included as quality controls. The end-point titre of the positive standard sera was recorded to determine interassay variation.
In seven sera of different end-point titres the ICA titres did not decrease when absorbed overnight at+4~ to 1 Ixg/ml human recombinant DNA insulin (Humulin Regular, Eli Lilly, Indianapolis, Ind, USA). The insulin absorption was performed to exclude a possible influence of insulin autoantibodies on the ICA immunofluorescence reaction.
Statistical analysis
Wilcoxon signed rank test was used to test differences in end-point titres between results obtained for the different rimes of incubations. Fisher's exact test was used to test difference in ICA prevalence between 30-min and 18-h incubation assay in the group of 70 Type 1 diabetic children. All tests were two-tailed. All data are presented as median and range. The standard deviation was calculated for the positive quality sample to get the interassay variation. 
Results
In the first series of experiments, sera from 30 Type 1 diabetic patients were incubated for 30 min, 18 h and 24 h (Fig. 1) ICA assay reproducibility and precision are rarely reported. ICA positive and negative quality control serum samples were therefore included in each assay at different dilutions. At the completion of this study, cumulated end-point titres of the quality control samples were plotted to visualize the interassay variation (Fig. 3) . The positive control serum had a median titre of I : 32 with a standard deviation of 0.74 titration steps for 30-min and for 18-h incubation the median titre was 1:256 and the standard deviation was 0.92 titration steps. The negative samples were found negative in every assay.
All samples were tested at 1:2 and 1:64 dilutions to identify possible positive samples before the final titration. The negative samples were analysed a second time in 1:8 dilution. In the group of 70 newly diagnosed Type I diabetic subjects, it was revealed that ICA positivity was not always observed at a 1 : 2 dilution but was observed at higher dilutions. This phenomenon, usually referred to as a prozone effect, was observed in the 30-min assay, but was most pronounced in the 18-h assay, where it occurred in 11 out of 70 samples (16%). The prozone positive samples had end-point titres between 1:8 and 1:260000, with the median titre 1 : 64.
The addition of human insulin to neutralize possible insulin autoantibodies prior to the ICA analysis did not decrease ICA end-point titres (data not shown).
Discussion
Recently we have shown that the two-colour immunofluorescence assay to determine ICA is a reproducible test which correlates closely to the conventional onecolour ICA assay [16] . A major advantage of the twocolour assay is the possibility to first identify the islet B cells and then to check whether these cells show ICA immunofluorescence. This procedure diminishes the risk of obtaining false negative ICA results, and it allowed us in one serum to identify ICA which did not stain the B cells. Counter-staining with glucagon antibodies showed this serum to contain ICA reactive with the A cells. In this study, we show that a prolonged incubation increases the end-point titres in recently diagnosed Type I diabetic patients, and thus confirms previous observations in the one-colour ICA assay [17] . A careful investigation of different incubation times revealed that the antibody-antigen equilibrium was reached after 18-h incubation. In comparison to the conventional 30-rain assay, the mean titre of the ICA positive samples increased by about two titration steps after 18-h incubation. The higher sensitivity of the 18-h ICA assay increased the prevalence of ICA among 70 consecutively newly diagnosed Type 1 diabetic patients. This increase in ICA prevalence and titres were not due to aprotinin itself, since experiments with and without aprotinin in the 30-rain incubation assay showed that the mere presence of aprotinin did not influence ICA titres. Therefore, time of incubation to allow maximal antibody binding rather than aprotinin was responsible for the increased sensitivity of the 18-h ICA assay. If the prolonged incubation was performed without aprotinin, the tissue could not be properly evaluated because of the proteolytic damage.
The recent attempts to standardize the ICA analysis [12, 13] showed that there was a marked variation between different laboratories in the sensitivity of the conventional one-colour 30-min ICA assay. The importance of a reproducible assay for prognostic studies is evident. We demonstrate that the 18-h two-colour assay shows a low interassay variation (Fig. 3) , by repeated determination of the end-point titre of a positive and a negative standard sample. In our ICA assay the end-point titre of the positive quality control sera varied by only 0.92 titration steps, and there was no drift in the ICA assay.
An important and unexpected finding was the observation that up to 16% of the sera were negative at the 1:2 dilution, although positive at higher dilutions. This phenomenon, commonly referred to as a prozone effect, is thought to be dependent on an excess of antibodies inhibiting both the normal antigen-antibody binding and also the accessibility of the second antibody to react with the first antibody. This effect was especially pronounced in the prolonged incubations. It therefore becomes necessary to screen all samples at various levels of dilutions. It remains to be determined whether the prozone positive samples are always of high titres. If so, the prozone effect could be the explanation why sera are sometimes reported negative for ICA but positive in the complement-fixing-ICA (CF-ICA) assay [19] , which has been found to be a less sensitive assay [12, 13] . The finding of insulin autoantibodies (IAA) in newly diagnosed Type i diabetic children prior to insulin therapy has been reported up to 30% [20] [21] [22] [23] [24] . In the 30-rain two-colour immunofluorescence ICA assay the end-point titres of ICA for IAA positive and ICA positive sera (IAA/ICA) correlated with those titres found in the conventional one-colour 30-rain ICA assay, indicating that IAA and the proinsulin antibody do not interfere and have different antigenic sites [16] . It was therefore tested whether higher titres in the 18-h twocolour ICA assay could be due to [AA, by adding excess of human recombinant insulin to the sample to preabsorb possible IAA. However, this did not influence the ICA end-point titres. In fact, the titres tended to be higher in the presence of insulin.
In the present study, 89% of the patients with recent onset Type I diabetes were ICA positive in the 18-h assay compared to 76% in the 30-rain assay. When our results are compared to those previously reported (Table 2 ), the present ICA prevalence is higher than in most other materials. One explanation may be the short latency from time of diagnosis to serum sampling, since the titre [12, 13] and prevalence [3, 5, 7] of ICA decrease with increasing duration of Type 1 diabetes. However, the main reason for the high prevalence of ICA in our study is likely to be the increased possibility of detecting islet cell antibodies in the 18-h assay. Titrations of ICA are of interest because a positive correlation between ICA levels and the rate of decrease in fasting C-peptide was found in Type I diabetic patients prospectively observed throughout a 2.5 year period [14] . If this phenomenon is also to be substantiated in future studies of ICA positive nondiabetic individuals, a wide range of titres would seem preferable. The 18-h two-colour assay (Fig.2) showed not only an increase in the median titre among the diabetic patients but also in the range of titres. Hitherto not reported, remarkably high titres (> 2 x 105) were found in some patients. The prolonged incubation therefore made it possible to more clearly delineate the ICA positive from the ICA negative group of diabetic individuals. This was also apparent among control subjects and siblings. The two control subjects and the two siblings with ICA showed titres well within the range of the ICA positive Type 1 diabetic patients. One of the siblings has now developed Type 1 diabetes, more than 2 years after the sample was taken. He is also HLA-DR identical to his diabetic sibling. Although further analyses are necessary, this indicates that ICA titration in the 18-h two-colour immunofluorescence test may be of better predictive value for identifying prediabetic subjects than just recording whether the autoantibodies are present or not. Hence, we suggest that the prolonged ICA assay is suitable in screening attempts to detect individuals at risk to develop Type 1 diabetes. Since the prediabetic period may be long even among children, an age group which remains tO be properly investigated, the present assay may better define individuals who have an active autoimmune process against the pancreatic islet cells. An early detection of prediabetic subjects will allow future tests of immune intervention or other measures in attempts to prevent a subsequent onset of the disease.
In conclusion, a prolonged incubation in the presence of aprotinin increases the sensitivity of the twocolour immunofluorescence test to determine ICA. In Type 1 diabetic patients, our 18-h two-colour immunofluorescence ICA assay demonstrates a wide range of ICA titres, increases the overall end-point titres of ICA, and clearly discriminates ICA positive from ICA negative serum samples.
